Addressing Technical Challenges in Development Drug Products: A CDMO Perspective

This presentation dives into ways Thermo Fisher Scientific has helped clients solve some of the technical challenges that can be faced during development of drug products. Watch now to learn how these solutions have helped bring effective medications and drug products to approval and to patients.

Author:
Anil Kane, Ph.D.
Senior Director, Global Technical Scientific Affairs

Related Sites

Additional Resources

Future Forward: How your outsourcing strategy shapes your development strategy

Hot melt extrusion: Improving solubility of poorly soluble compounds

QP Release – expectations and responsibilities for clinical and commercial drug products in Europe

Fixed dose combination drug development: Designing a lifecycle strategy with agility & speed

Impact of a Pandemic Outbreak on Vaccine Development Approach

Lyophilization: Small-Large Scale Comparability

A Quality by Design Approach to Optimize Tablet Formulations containing PVP VA64 Amorphous Dispersions: Formulation Variables

Discrete Element Modeling of a Pharmaceutical Blending Process

Evaluation of a Quality by Design (QbD) Approach for Process Development and Scale-Up of a Novel ALS Drug Product

Enhanced Solubilization of an Analgesic/Antipyretic Drug With The Use of Polymeric Excipients

Addressing Technical Challenges in Development Drug Products: A CDMO Perspective

Accelerating Cell Culture Development through Practical Application of Innovation Technologies

Technology Transfers Best Practices for Optimizing Success and Mitigating Risk

Using Quality By Design For Process Development And Scale-Up Of A Novel ALS Drug Product

CMO Scorecard Trend Report

Early Development Fact Sheet

Quadrant 2 ®: Predictive Platform for Solubility and Bioavailability Enhancement

Infographic: A Tale of Two Molecules

Infographic: 8 Criteria for a More Successful API Partnership

Webinar: Post Pandemic Planning: What Will Change in Early-Phase Drug Development?

Drug Repurposing Trends—A CDMO Perspective

Challenge Accepted: Biopharma Puts COVID-19 in Its Pipeline

Ensuring the Greatest Return From Your Poorly Soluble Molecule

Strategies for API Solubility and Bioavailability Enhancement

Flexible Solutions to Speed Your Molecules to Phase I Clinical Trials

The Pharma Trends You Need to Know: A CDMO’s Perspective

How Well Should You Understand Your Crystallization Process (and Solid-State Properties)?

Quality by Design: A Holistic Approach to Drug Development

Phase-Appropriate Formulation Development & Manufacturing for Parenteral Dosage Forms

Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs

Rise in Targeted Therapies Drives Need for Small-Volume Manufacturing

Are You Prepared for the Complexity of Pediatric Drug Development?

Novel Uses for Oral Solid Doses Driving Lifecycle Management Strategies

Challenges in the Development of Complex Small-Molecule Drugs

Ensure the Scalability of Your Molecule with a Science-Driven, Phase-Appropriate Approach

The Race to Phase III: A Cautionary Tale of Scalability

Avoid the Do-Over: Why Early Investment in a Scalable Manufacturing Process Is Critical

Anticipating the Formulation Challenges of Complex Molecules

Phase Appropriate Formulation and Process Design

What to Look For in a Solubility Enhancement Vendor

Amorphous Dispersion Drug Formulations: A Modern Simulation-Based Approach

The Advantages of Employing a Lipid-Based Formulation Process in Early Development

Early Stage Development for Solid Dose Products

How Broadening the Analysis of Compound Factors Allows for Predictive Solubility Solutions

Taking An Informed Approach To Technology Selection To Address Solubility Challenges In Early Development

Taking a More Informed Approach to Solubility Enhancement

© 2021 Thermo Fisher Scientific Inc. All rights reserved. Cookie Use Privacy Terms of Use Modern Slavery Statement

Cookie Use Privacy Terms of Use Modern Slavery Statement

© 2021 Thermo Fisher Scientific Inc. All rights reserved.